Home › Compare › STRCW vs ABBV
STRCW yields 4000.00% · ABBV yields 3.06%● Live data
📍 STRCW pulled ahead of the other in Year 1
Combined, STRCW + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of STRCW + ABBV for your $10,000?
Sarcos Corp., a robotics and sensor company, designs, builds, and produces dexterous tele-operated robotic systems. Its products include Guardian S, an unmanned ground vehicle for security, inspection, and non-destructive testing available in a Robot-as-a-Service offering; Guardian GT, a big arm system or dual-armed human-controlled robot mounted on an agile tracked vehicle base for commercial, industrial, and first responder environments; and Guardian XO, a robot that features an exoskeleton suit; SenSuit controller garment for enhanced teleoperation of the Guardian XT (a highly dexterous mobile robotic system); and humanoid solutions. The company also provides advanced robotic systems for industry, entertainment; medical devices, including artificial limbs and vascular systems; and mechanical and electrical microsystems for practical applications. The company serves healthcare, life sciences, telecommunications, robotics, defense, and entertainment industries. Sarcos Corp. was founded in 1983 and is based in Salt Lake City, Utah with an additional office in Bellevue, Washington. Sarcos Corp. is a former subsidiary of Raytheon Company.
Full STRCW Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.